Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2018

Hong, Seri; Won, Young‐Joo; Lee, Jae Jun; Jung, Kyu-Won; Kong, Hyun‐Joo; Im, Jeong-Soo; Seo, Hong Gwan

doi:10.4143/crt.2021.291

Cited by 257 publications

(231 citation statements)

References 5 publications

Supporting

Mentioning

208

Contrasting

Unclassified

Order By: Relevance

“…The incidence of thyroid cancer has increased in recent years, being the most commonly detected cancer in the USA (52,070 new cases in 2019) [ 1 ]. It is also the second most frequently diagnosed cancer in Korea [ 2 ]. Cancer biomarkers can be classified into three broad categories: DNA, RNA, and protein markers.…”

Section: Introductionmentioning

confidence: 99%

Quercetin Induces Anticancer Activity by Upregulating Pro-NAG-1/GDF15 in Differentiated Thyroid Cancer Cells

Hong

Lee

Moon

et al. 2021

Cancers

View full text Add to dashboard Cite

Although the treatment of thyroid cancer has improved, unnecessary surgeries are performed due to a lack of specific diagnostic and prognostic markers. Therefore, the identification of novel biomarkers should be considered in the diagnosis and treatment of thyroid cancer. In this study, antibody arrays were performed using tumor and adjacent normal tissues of patients with papillary thyroid cancer, and several potential biomarkers were identified. Among the candidate proteins chosen based on the antibody array data, mature NAG-1 exhibited increased expression in tumor tissues compared to adjacent normal tissues. In contrast, pro-NAG-1 expression increased in normal tissues, as assessed by western blot analysis. Furthermore, pro-NAG-1 expression was increased when the thyroid cancer cells were treated with phytochemicals and nonsteroidal anti-inflammatory drugs in a dose-dependent manner. In particular, quercetin highly induced the expression of pro-NAG-1 but not that of mature NAG-1, with enhanced anticancer activity, including apoptosis induction and cell cycle arrest. Examination of the NAG-1 promoter activity showed that p53, C/EBPα, or C/EBPδ played a role in quercetin-induced NAG-1 expression. Overall, our study indicated that NAG-1 may serve as a novel biomarker for thyroid cancer prognosis and may be used as a therapeutic target for thyroid cancers.

show abstract

Section: Introductionmentioning

confidence: 99%

Quercetin Induces Anticancer Activity by Upregulating Pro-NAG-1/GDF15 in Differentiated Thyroid Cancer Cells

Hong

Lee

Moon

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…In general, the incidence rate is higher in East Asia than in North America. In South Korea, newly updated data show that GC accounted for the highest cancer incidence and the 4 th most frequent cause of cancer-related death in 2018 (2) .…”

Section: Introductionmentioning

confidence: 99%

Riboflavin intake, MTRR genetic polymorphism (rs1532268) and gastric cancer risk in a Korean population: a case–control study

Gunathilake

Lee

et al. 2021

Br J Nutr

View full text Add to dashboard Cite

The vitamin B group, including riboflavin, plays paramount roles in one-carbon metabolism (OCM), and disorders related to this pathway have been linked to cancer development. The variants of genes encoding OCM enzymes and the insufficiency of B vitamins could contribute to carcinogenesis. Very few observational studies have revealed a relationship between riboflavin and gastric cancer (GC), especially under conditions of modified genetic factors. We carried out a study examining the association of riboflavin intake and its interaction with MTRR (rs1532268) genetic variants with GC risk among 756 controls and 377 cases. The odds ratios (ORs) and 95% confidence intervals (CIs) were evaluated using unconditional logistic regression models. We observed protective effects of riboflavin intake against GC, particularly in the female subgroup (OR=0.52, 95% CI 0.28-0.97, p-trend=0.031). In the MTRR (rs1532268) genotypes analysis, the dominant model showed that the effects of riboflavin differed between the CC and CT+TT genotypes. Compared with CC carriers, low riboflavin intake in T+ carriers was significantly associated with a 93% higher GC risk (OR=1.93, 95% CI 1.09-3.42, p-interaction=0.037). In general, higher riboflavin intake might help reduce the risk of GC in both CC and TC+TT carriers, particularly the T+ carriers, with marginal significance (OR=0.54, 95% CI 0.28-1.02, p-interaction=0.037). Our study indicates a protective effect of riboflavin intake against GC. Those who carry at least one minor allele and have low riboflavin intake could modify this association to increase GC risk in the Korean population.

show abstract

“…Additionally, 18.1 million patients were diagnosed with cancer in 2018, highlighting the impact of cancer across the world [ 1 ]. In Korea, cancer is also a major cause of death, and the incidence and mortality rates of cancer in 2018 were 270.4 and 268.3 per 100,000, respectively, accounting for 26.5% of all deaths [ 2 ]. Although advances in medical technology have improved cancer mortality in many countries, some cancers remain difficult to treat [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Post-Diagnostic Statin Use Reduces Mortality in South Korean Patients with Dyslipidemia and Gastrointestinal Cancer

Han

Kim

2021

JCM

View full text Add to dashboard Cite

Background: Statins play a role in lowering serum cholesterol and are known to have pleiotropic effects in a variety of diseases, including cancer. Despite the beneficial effects of statins in dyslipidemia patients, the treatment rate for dyslipidemia in Korea remains low, and evidence supporting the continued use of statins is lacking. The purpose of this study was to evaluate the effect of continued statin use and dosage on patient mortality after diagnosis of dyslipidemia and gastrointestinal (GI) cancer. Methods: We used data from the National Health Insurance Sampling (NHIS) cohort to evaluate patients diagnosed with dyslipidemia from 2002 to 2015. A total of 901 GI cancer patients with dyslipidemia and 62,727 non-cancer dyslipidemia patients were included in the study. During the study period, each patient’s medication possession ratio (MPR) after diagnosis was evaluated as a measure of continued statin use. Statin dosage was measured based on a defined daily dose (DDD). Finally, we used Cox-proportional hazard ratios to identify associations between the continual use of statins and mortality in patients with dyslipidemia and GI cancer. Results: In our study, mortality decreased with increasing MPR and reached significance in MPRs exceeding 50% for GI cancer patients and 75% for dyslipidemia patients compared to patients that did not use statins. Moreover, patients with high MPRs had significantly reduced 5-year mortality compared to non-users, and cause-specific mortality analyses revealed that high MPR was associated with decreased colorectal cancer death. We did not find a significant dose–response relationship between statins and mortality. Conclusion: Our findings suggest that continued statin use after diagnosis is associated with reduced patient mortality. Altogether, these results support the continued use of statins in dyslipidemia patients with and without GI cancer and highlight the importance of patient education by healthcare providers.

show abstract

Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2018

Cited by 257 publications

References 5 publications

Quercetin Induces Anticancer Activity by Upregulating Pro-NAG-1/GDF15 in Differentiated Thyroid Cancer Cells

Quercetin Induces Anticancer Activity by Upregulating Pro-NAG-1/GDF15 in Differentiated Thyroid Cancer Cells

Riboflavin intake, MTRR genetic polymorphism (rs1532268) and gastric cancer risk in a Korean population: a case–control study

Post-Diagnostic Statin Use Reduces Mortality in South Korean Patients with Dyslipidemia and Gastrointestinal Cancer

Contact Info

Product

Resources

About